Suven Life Sciences, a Hyderabad based life sciences company, has suffered setback during the second quarter ended September 2007 due lower revenue from CRAMS business. The company's net profit declined sharply by 53.4 per cent to Rs 1.16 crore from Rs 2.49 crore in the similar period of last year. The net sales were marginally lower at Rs 27.84 crore as against Rs 27.88 crore. The earning per share for the quarter worked out to Rs 0.10 as compared to Rupee 1 in the last period. The revenue from CRAMS declined 13 per cent to Rs 20.95 crore from Rs 24.07 crore. However, the income from Drug Discovery Development Support Services (DDDSS) services increased to Rs 6.89 crore from Rs 3.80 crore.
For the first half of 2007-08, the company's net sales increased by 5.8 per cent to Rs 56.55 crore from Rs 53.45 crore. The net profit, however, went down by 5.7 per cent to Rs 4.31 crore from Rs 4.57 crore in the last year. The profit before interest, depreciation and taxation also declined by 8.9 per cent to Rs 6.88 crore from Rs 7.55 crore. Its R&D expenditure for the first six months ended September 2007 increased to RS 8.97 crore from Rs 7.88 crore. Revenues from CRAMS reached at Rs 46.47 crore as against Rs 47.97 and that from DDDSS services increased to Rs 10.09 crore from Rs 5.48 crore.